Addiction最新文献

{"title":"Adolescent use of nicotine pouches in four Latin American countries: A cross-sectional survey.","authors":"Georgia Alexandrou, Crawford Moodie, Catherine Best, Inti Barrientos-Gutierrez, Carlos Miguel Aguilar, Mariel Palacios, James F Thrasher","doi":"10.1111/add.70617","DOIUrl":"https://doi.org/10.1111/add.70617","url":null,"abstract":"<p><strong>Background and aim: </strong>Nicotine pouches are novel products with rapid global sales growth. Our aim was to explore use and perceptions of nicotine pouches among adolescents in Latin America.</p><p><strong>Design: </strong>Cross-sectional school surveys between March and August 2025.</p><p><strong>Setting: </strong>Sixteen cities, four each in Argentina, Guatemala, Mexico and Peru.</p><p><strong>Participants: </strong>Adolescents aged 12-17 years (n = 12 785).</p><p><strong>Measurements: </strong>Use of, and susceptibility to, nicotine pouches, through survey questions about frequency of use, brands and flavours used, access, and harm compared to cigarettes and e-cigarettes.</p><p><strong>Results: </strong>Self-reported ever use was 6.0%, highest in Peru (9.1%) and lowest in Argentina (3.2%). Ever use was higher among males, those with higher family affluence scores, and those who had ever vaped or smoked tobacco. The rate of current (past 30 day) nicotine pouch use was 2.4%. Those reporting current use typically used pouches infrequently (1-3 days in the last month). The most commonly used brands were Velo (24.4%) and Zyn (18.1%), with pouches most likely to be given to them by someone (26.3%) or giving someone else money to buy them (15.8%). Fruit (20.3%) and mint/menthol (17.3%) were the most common flavours reported. More than one-third of the sample indicated that nicotine pouches were more harmful (somewhat/a lot) than cigarettes (38.7%) and e-cigarettes (36.7%).</p><p><strong>Summary: </strong>Nicotine pouch use among adolescents in four Latin American countries appears to be relatively uncommon but higher than in previous youth surveys. Access to nicotine pouches appears to be largely informal, fruit and mint/menthol flavours are most common, and many adolescents appear uncertain about harm compared with cigarettes and e-cigarettes.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Craving and the body: Sensations of cue-elicited craving in binge drinking university students.","authors":"Pauline Billaux, Olivier Desmedt, Nicolas Cabé, Joël Billieux, Alice Laniepce, Mateo Leganes-Fonteneau, Arthur Pabst, Anne-Lise Pitel, Pierre Maurage","doi":"10.1111/add.70609","DOIUrl":"https://doi.org/10.1111/add.70609","url":null,"abstract":"<p><strong>Background and aims: </strong>Theoretical models of addiction identify craving as a key symptom, but its investigation has been mostly confined to its neurocognitive, psychological and behavioral facets, leaving its other dimensions unexplored. Beyond these approaches, craving could also have a strong bodily component. We explored the bodily sensations of craving in a subclinical population of excessive drinkers.</p><p><strong>Design: </strong>Observational study. Following a multimodal craving induction, participants reported the bodily manifestations of their current craving state through a body mapping procedure.</p><p><strong>Setting: </strong>Laboratory study at UCLouvain, Louvain-la-Neuve, Belgium.</p><p><strong>Participants: </strong>Ninety-one (53 females) young adults (mean age = 20.35, standard deviation = 2.13) with a heavy episodic pattern of alcohol consumption (binge drinkers, BD).</p><p><strong>Measurements: </strong>We assessed four dimensions of bodily craving: the type of sensations felt (i.e. taxonomy, assessed by asking participants to name the bodily sensations associated with craving), where in the body they were felt (i.e. localization, assessed by asking participants to indicate in which area of the body these sensations manifested), how intense they were (i.e. intensity, assessed by asking participants to rate through crosses the strength of these sensations) and their overall agreeability [i.e. pleasantness, assessed by instructing participants to rate through numbers how (un)pleasant these sensations were].</p><p><strong>Results: </strong>BD reported bodily sensations of craving most often and with the highest intensity in the mouth (84.62% of participants reported sensations in this body part, mean intensity = 0.51 on a scale from 0 to 1), shoulders/thorax (51.65% of participants, mean intensity = 0.23) and hands (53.85% of participants, mean intensity = 0.21). These sensations principally manifested as salivation (45.45%), palpitations (56.25%) and tremors (38.00%), respectively. Pleasantness ratings ranged from unpleasant (e.g. for perspiration in the shoulders and thorax) to pleasant (e.g. for ease in the abdomen).</p><p><strong>Summary: </strong>Among binge drinkers, craving does not appear to be exclusively a psychological phenomenon but also encompasses various and strong bodily sensations. Bodily craving for alcohol encompasses both positive sensations resembling those felt when experiencing pleasurable acute alcohol effects (e.g. relaxation/ease in upper parts of the body) but also negative ones close to those reported in alcohol withdrawal (e.g. tremors, perspiration).</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"50 years of experience with a comprehensive alcohol advertising ban in Norway.","authors":"Stig Erik Sørheim","doi":"10.1111/add.70621","DOIUrl":"https://doi.org/10.1111/add.70621","url":null,"abstract":"<p><strong>Background and aims: </strong>Alcohol is one of the leading preventable risk factors for mortality and morbidity in Europe. The World Health Organization has identified advertising restrictions or bans as one of the three best buys to reduce alcohol-related harms, along with taxation and restrictions on availability. Norway is one of the countries with the strongest regulations on alcohol advertising; the Norwegian Alcohol Act, which came into effect in July 1975, bans all forms of alcohol marketing to Norwegian audiences. This paper gives an overview of the history of the alcohol advertising ban, the political process and debate leading up to the ban, the main elements of the ban and the legal challenges to the ban over its 50-year history.</p><p><strong>Methods: </strong>Review of key government documents, bills and parliamentary reports leading up to the adoption of the ban, as well as legal cases, grey literature and research on the alcohol advertising ban in Norway.</p><p><strong>Results: </strong>The Norwegian Alcohol Act bans alcohol advertising, defined as mass communication for marketing purposes. The ban applies to all media channels that target Norwegian audiences. The marketing ban is an integral part of a comprehensive set of alcohol control measures. The alcohol advertising ban has been challenged legally on several occasions, and the courts have helped clarify the boundaries of the ban. The ban has also proven flexible enough to adapt to new circumstances, such as the emergence of alcohol-free beers and marketing in social media. A comprehensive ban has some advantages compared with more limited advertising restrictions, with fewer loopholes and greater protection from exposure. To this day the advertising ban enjoys broad popular support; however, calls to modernize the legislation may undermine its comprehensive nature.</p><p><strong>Summary: </strong>Norway's 1975 comprehensive ban on alcohol advertising has proven to be a flexible tool to limit exposure to alcohol advertising, although changing circumstances present new challenges.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving the identification and monitoring of cannabis use disorder in Canada.","authors":"Robert Gabrys","doi":"10.1111/add.70623","DOIUrl":"https://doi.org/10.1111/add.70623","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149101392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial.","authors":"Megan S Schuler, Rebecca Weir, Colleen M McCullough, Grace M Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S Meredith, Katherine E Watkins","doi":"10.1111/add.70503","DOIUrl":"10.1111/add.70503","url":null,"abstract":"<p><strong>Background and aims: </strong>Individuals with opioid use disorder (OUD) frequently present with co-occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise 'clinical complexity.' Collaborative care (CC), a primary care-based behavioral health integration model, aims to improve outcomes through coordinated, patient-centered treatment. This study examined heterogeneity in baseline clinical complexity among participants in the CLARO (Collaboration Leading to Addiction Treatment and Recovery from Other Stresses) trial and assessed whether the effects of CC versus enhanced usual care (EUC) differed across clinical complexity groups.</p><p><strong>Methods: </strong>Secondary analysis of CLARO, a pragmatic randomized clinical trial (n = 797) of CC versus EUC for adults with OUD and depression and/or PTSD, conducted in 18 low-resourced primary care clinics in New Mexico and California, USA. Latent class analysis of baseline data identified subgroups defined by mental health and substance use as the main characteristics along with physical health and social challenges. Six-month treatment effects were estimated using one-step models that jointly estimated latent class membership and class-specific outcomes, incorporating class × treatment interactions. Outcomes included depression symptom severity, PTSD symptom severity, and buprenorphine utilization and prescribing duration.</p><p><strong>Results: </strong>Three subgroups were identified: (1) low complexity (43%), with relative clinical and social stability; (2) mental health complexity (34%), with high psychiatric symptoms but lower substance use and moderate social adversity; and (3) high dual complexity (23%). Compared with EUC, CC was associated with lower depression severity at follow-up for the low-complexity class, but not for other classes. CC and EUC did not differ statistically significantly with respect to PTSD outcomes in any class. Buprenorphine utilization and prescribing duration outcomes were similar across CC and EUC treatment arms.</p><p><strong>Conclusions: </strong>The effects of collaborative care may vary according to patients' baseline clinical complexity. Collaborative care appears to be associated with more favorable depression outcomes than enhanced usual care among participants with lower clinical complexity but not among those with higher clinical complexity.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"2833-2844"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148238688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all-cause mortality among people with opioid use disorder: A retrospective population-based target trial emulation study in British Columbia, Canada, 2010-2020.","authors":"Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk","doi":"10.1111/add.70489","DOIUrl":"10.1111/add.70489","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long-term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment. Current clinical practice guidelines offer relatively limited guidance or evidence on the appropriate timing to initiate a taper. We aimed to determine the safety and comparative effectiveness of different times from completion of OAT induction at which tapering could be considered to maximize the likelihood of taper completion and minimize the risk of mortality.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Population-based retrospective observational study and target trial emulation based on nine linked administrative health databases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;British Columbia, Canada, from 1 January 2010 to 17 March 2020.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Individuals (identified via linkage of nine provincial health administrative databases) completing OAT induction with methadone or buprenorphine/naloxone who were ≥18 years of age with no known pregnancy, no history of cancer or palliative care and not currently incarcerated. We executed both incident-user (no OAT experiences) and prevalent-new-user (no OAT within the past month) analyses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention and comparator: &lt;/strong&gt;The time between completed OAT induction and taper initiation: &lt;3 months, 3-6 months, 6-12 months, compared with 12-48 months.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;The primary outcomes were completed taper (reaching a final daily dose of ≤5 mg/day for methadone, or ≤2 mg/0.5 mg/day for buprenorphine/naloxone) and all-cause mortality. A clone-censor-weight approach was used to adjust for informative censoring and balance baseline characteristics between the groups. Logistic regression and pooled logistic regression models were used to estimate odds ratios (ORs) for completed taper and hazard ratios (HRs) for all-cause mortality, respectively, each with 95% compatibility ('confidence') intervals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;We included 17 726 incident users (buprenorphine/naloxone: 36.9%) and 49 515 treatment episodes (buprenorphine/naloxone: 31.2%) from 31 231 prevalent new users who completed induction in the analyses. Among prevalent new users, beginning tapering within 3 months, between 3 and 6 months and between 6 and 12 months of completing induction was associated with an increased likelihood of completed taper [methadone: &lt;3 months: adjusted odds ratio (aOR) = 3.09, 95% compatibility interval (95% CI) = 2.58-3.68; buprenorphine/naloxone: &lt;3 months: aOR = 6.90, 95% CI = 5.19-9.16] but a higher risk of mortality [methadone: &lt;3 months: adjusted hazard ratio (aHR) = 1.18, 95% CI = 1.12-1.25; buprenorphine/naloxone: &lt;3 months: aHR = 1.12, 95% CI = 1.05-1.19], compared with initiating a taper between 12 and 48 months. Similar results were found among incident ","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"2794-2806"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial.","authors":"Jennifer McNeely, Geetha A Subramaniam, Rebecca Stone, Shayna Mazel, Noa Appleton, Yasna Rostam-Abadi, Amanda M Bunting, Yidan Shi, Travis I Lovejoy, Lillian Gelberg, Donna Beers, Margaret Kline, Song Zhang, Tobie Kim, Ashley Case, Jennifer McCormack, Michael A Incze, Jane M Liebschutz","doi":"10.1111/add.70504","DOIUrl":"10.1111/add.70504","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;Individuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care-integrated collaborative care approach for reducing risky opioid use, defined as nonmedical use of prescription opioids or any use of illicit opioids.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Cluster-randomized controlled trial randomized primary care providers (PCPs) and their patients into the Subthreshold Opioid Use Disorder Prevention (STOP) intervention or enhanced usual care (EUC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Primary care clinics at 5 U.S. sites.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;PCPs and their patients were recruited January 2021-May 2023. A total of 119 PCP clusters (STOP = 48, EUC = 51) and 202 patients (STOP = 88, EUC = 114) enrolled. Eligible patients were adults (≥18 years) having current risky opioid use, without moderate-severe OUD. Patient participants were majority female (63.4%), white (70.8%) and non-Hispanic (96.5%), with a mean age of 55.7 [standard deviation (SD) = 12.7] years. At baseline, 63.4% of participants had moderate-severe pain (Brief Pain Inventory) and below average physical (79.2%) and mental (62.4%) health (SF-12).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;The STOP collaborative care intervention consisted of brief advice from the PCP about reducing risky opioid use, meetings with a clinic-embedded nurse care manager over 12 months and remote health coaching (2-6 sessions). Both groups received primary care treatment as usual and overdose risk reduction materials.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;The primary outcome was total days of risky opioid use, recorded from 6 monthly electronic surveys. A key secondary outcome was moderate-severe OUD at 6 and 12 months.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;A total of 77 (87.5%) STOP and 107 (93.9%) EUC participants completed the 6-month assessment period. The primary outcome analysis used the Intention-to-Treat sample with multiple imputations of missing data. Mean days of risky opioid use at 180 days were lower in STOP than EUC [12.2 (SD = 27.73) vs. 15.5 (SD = 32.64)]; the difference between groups adjusted for baseline risky opioid use was not statistically significant (rate ratio 0.95, 95% confidence interval = 0.52-1.74). One STOP participant (1.1%) and 13 EUC participants (11.4%) developed moderate-severe OUD at 6 months, and 3 (3.4%) STOP and 6 (5.3%) EUC participants had moderate-severe OUD at 12 months (P &lt; 0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This cluster-randomized controlled trial did not find evidence that the STOP intervention for reducing risky opioid use produced greater reductions over 6 months compared with enhanced usual care, though fewer intervention participants progressed to moderate-severe opioid use disorder. Patients had a high burden of","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"2807-2821"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148300426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The United Kingdom's Tobacco and Vapes Act 2026-A landmark in tobacco control, but a missed opportunity for product clarity.","authors":"Sharon Cox, Caitlin Notley, Robert West","doi":"10.1111/add.70528","DOIUrl":"10.1111/add.70528","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"2852-2853"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148325338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in new psychoactive substance poisonings in the Netherlands: A 14-year retrospective analysis (2012-2025).","authors":"Johanna J Nugteren-van Lonkhuyzen, Irma S van den Hengel-Koot, Claudine C Hunault, Dylan W de Lange, Antoinette J H P van Riel, Laura Hondebrink","doi":"10.1111/add.70511","DOIUrl":"10.1111/add.70511","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;Data on the presence of new psychoactive substances (NPS) mainly originate from drug-checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands. We investigated temporal trends in NPS poisonings reported to the Dutch Poisons Information Center (DPIC) between 2012 and 2025 and compared these trends across NPS categories.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;National observational study based on retrospective extraction of recreational drug poisonings (including NPS) from the DPIC database from 2012 to 2025. The DPIC is not accessible to the general public and reporting by healthcare professionals is voluntary.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting/cases: &lt;/strong&gt;The DPIC database contains standardized case report forms with anonymous patient data and individually (self-)reported substance exposures (not ICD-coded, not analytically confirmed). All cases concerning human exposures to recreational drugs recorded in the DPIC database were included.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;Primary outcomes were the annual number and annual incidence rate of NPS poisonings reported to the DPIC, relative to the annual number of all recreational drug poisonings. Secondary outcomes were incidence rates of specific (categories of) NPS over time. Predictor was the year of report.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between 2012 and 2025, healthcare professionals reported 19 316 recreational drug poisonings, including 4289 NPS-related poisonings, while seeking advice on patient management. The annual number of NPS poisonings increased from 32 in 2012 to 829 in 2025. Between 2012 and 2025 the annual incidence rate of NPS poisonings increased statistically significantly by 19% per year [incidence rate ratio = 1.19; 95% confidence interval (CI) = 1.15-1.23]. A higher incidence rate of NPS poisonings was observed in July and December. Cathinones, phenethylamines and benzodiazepines represented 83% of all NPS poisonings. Benzodiazepines were predominant in 2012 and 2024, phenethylamines from 2013 to 2018 and cathinones from 2019 to 2023 and in 2025. The total number of unique NPS notified to the DPIC increased from 17 in 2012 to 176 in 2025. Poisonings with 3-methylmethcathinone (3-MMC), bromazolam, 4-fluoroamphetamine (4-FA), 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and 4-methylmethcathinone (4-MMC, mephedrone) were reported most frequently (5-22% of 4289 NPS poisonings). Poisonings with arylcyclohexylamines, cannabinoids, opioids, arylalkylamines, tryptamines (indolalkylamines), piperidines and pyrrolidines and other substances were rare (every category &lt;5% of 4289 NPS poisonings). No poisonings with aminoindanes or piperazines were reported from 2012 to 2025.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The annual incidence rate of new psychoactive substances poisonings reported to the Dutch Poisons Information Center increased","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"2822-2832"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol-free and low-alcohol beverage consumption and concurrent and subsequent alcohol outcomes among young adults.","authors":"Samuel Mann, Daniel Siconolfi, Anthony Rodriguez, Rachana Seelam, Eric R Pedersen, Michael Dunbar, Elizabeth J D'Amico","doi":"10.1111/add.70514","DOIUrl":"10.1111/add.70514","url":null,"abstract":"<p><strong>Background and aims: </strong>Alcohol-Free and Low-Alcohol Beverages (AFLABs) have grown in popularity, yet predictors and longitudinal outcomes of their use remain unclear. We aimed to measure the association between AFLAB consumption and (1) concurrent and (2) subsequent alcohol consumption, risk and change measures (e.g. consequences, quit attempts, abstention) and drinking motives among young adults.</p><p><strong>Design: </strong>Observational study using two survey waves (W15 and W16; 2022-2024) from a longitudinal cohort study (STRATA).</p><p><strong>Setting: </strong>California, USA (surveys fielded 2022-2024).</p><p><strong>Participants: </strong>Cross sectional analysis of young adults (n = 877 individuals, of which 849 were followed in W16) who report past-month alcohol consumption in W15 from a California-based cohort study, and analysis of those with past-month alcohol consumption at both W15 and W16 (n = 693).</p><p><strong>Measurements: </strong>Individuals completed survey items on past-month AFLAB consumption, alcohol consumption (past-month heavy episodic drinking and past-year abstention), alcohol risk and change measures (alcohol-related consequences, indicators of a change effort and the alcohol contemplation ladder) and drinking motives (from the drinking motives questionnaire).</p><p><strong>Findings: </strong>Twenty-four percent of participants reported past-month AFLAB use at baseline. Adjusted cross-sectional models using W15 data indicated that AFLAB use was associated with lower social drinking motives [coefficient = -0.005; 95% confidence interval (CI) = -0.011 to 0.0001] but was not statistically significantly associated with other alcohol consumption, risk or change measures. In adjusted prospective models, baseline AFLAB use was associated with a 5.1 percentage point (pp) higher probability of alcohol abstention at W16 (95% CI = 1.1-9.1) than lack of AFLAB use. In adjusted prospective models, baseline AFLAB use was not statistically significantly associated with heavy episodic drinking, alcohol-related consequences or most change-related measures, although there was suggestive evidence of a higher likelihood of reporting a quit attempt in the past 3 months.</p><p><strong>Conclusions: </strong>Use of alcohol-free and low-alcohol beverages appears to be common among young adults in California, USA, and appears to be concurrently associated with lower social drinking motives and prospectively associated with subsequent alcohol abstention.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"2845-2851"},"PeriodicalIF":5.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13286231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148282963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}